Exelixis | EXEL - Creditori Commerciali





Creditori Commerciali Cambiamento Data
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
Akebia Therapeutics USD 8.39M 12.8M 2026-03
Amgen USD 19.52B 1.37B 2026-03
AstraZeneca USD 22.51B 2.78B 2026-03
Bayer EUR 6.59B 496M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 4.23B 659M 2026-03
Cytokinetics USD 24.71M 80.91M 2026-03
Eisai JPY 75.89B 9.6B 2026-03
Eli Lilly USD 5.03B 350M 2026-03
Esperion Therapeutics USD 68.41M 3.34M 2026-03
Exelixis USD 24.15M 5.47M 2026-03
Genmab DKK 6M 2M 2025-09
Glaxosmithkline GBP 14.34B 6.39B 2026-03
Incyte USD 228.62M 1.41B 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
MacroGenics USD 4.29M 500K 2026-03
Merck USD 3.86B 541M 2026-03
Moderna USD 161M 156M 2026-03
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.32B 134M 2026-03
Pfizer USD 4.51B 734M 2026-03
Puma Biotechnology USD 6.39M 962K 2025-09
Sanofi EUR 22.71B 219M 2026-03
Takeda JPY 491.34B 23.75B 2026-03
Ultragenyx Pharmaceutical USD 42M 11M 2026-03
Xencor USD 7.92M 2.91M 2026-03